HK Innoen 'K-Cab' Obtains Product Approval in Malaysia

HK Innoen's gastroesophageal reflux disease treatment, K-CAB, has obtained product approval in Malaysia.

HK Inno.N's gastroesophageal reflux disease treatment 'K-CAB'
Photo by HK Inno.N

HK Innoen announced on the 26th that K-CAB tablets recently received product approval from Malaysia's National Pharmaceutical Regulatory Agency (NPRA). Distribution will be handled by Pharmaniaga, Malaysia's top pharmaceutical company, with which a finished product export contract was signed in 2021.

K-CAB was approved in Malaysia for four indications: ▲treatment of erosive gastroesophageal reflux disease ▲treatment of non-erosive gastroesophageal reflux disease ▲treatment of gastric ulcers ▲antibiotic combination therapy for Helicobacter pylori eradication in patients with peptic ulcers and chronic atrophic gastritis. The local product name will remain K-CAB, the same as in Korea. The goal is to launch locally in Malaysia in the first half of next year.

K-CAB is currently available in a total of 46 countries including Korea, the United States, and China, with actual launches completed in 9 of these countries. In Southeast Asia, it is available to patients in the Philippines, Indonesia, and Singapore. The Southeast Asian market for peptic ulcer drugs is valued at $520 million (approximately 691 billion KRW), indicating promising growth potential.

Kwack Dal-won, CEO of HK Innoen, said, “K-CAB is accelerating market penetration by entering major Southeast Asian countries,” adding, “We will enhance the status of domestic new drugs by establishing K-CAB as the leading potassium-competitive acid blocker (P-CAB) product in the global market beyond Southeast Asia.”

This content was produced with the assistance of AI translation services.